Business UpdateJun 30, 2026, 08:58 AM
Artelo Biosciences Uncovers ART26.12's Mechanistic Link via Multi-Omics
AI Summary
Artelo Biosciences announced results from multi-omics analyses for its lead drug candidate, ART26.12, presented at the International Cannabinoid Research Society (ICRS) 2026 Annual Symposium. The analyses identified a potential mechanistic link across various disease models, showing consistent modulation of the pro-inflammatory lipid linoleic acid and related pathways. This discovery strengthens the understanding of FABP5 biology and supports the broad therapeutic potential of ART26.12, which is currently in Phase 1 testing for conditions like chemotherapy-induced peripheral neuropathy.
Key Highlights
- Artelo Biosciences announced multi-omics analysis results for ART26.12 at ICRS 2026 Annual Symposium.
- Analyses identified a potential mechanistic link across disease models for ART26.12.
- The findings revealed consistent modulation of pro-inflammatory lipid linoleic acid.
- This suggests broad therapeutic activity for Fatty Acid Binding Protein 5 (FABP5) inhibition.
- ART26.12 is Artelo's lead selective FABP5 inhibitor, currently in Phase 1 testing.
- The drug is being developed as a non-opioid analgesic for chemotherapy-induced peripheral neuropathy (CIPN).
Price Impact
More from ARTL